-+ 0.00%
-+ 0.00%
-+ 0.00%

Cocrystal Pharma Expects To Initiate CDI-988 Phase 1b Norovirus Challenge Study In Q1 2026

Benzinga·11/14/2025 13:29:35
Listen to the news
  • Received FDA IND clearance to evaluate CDI-988 as both norovirus preventive and treatment
  • Expects to initiate CDI-988 Phase 1b norovirus challenge study in Q1 2026
  • Granted NIH SBIR award to advance influenza A/B replication inhibitor program

BOTHELL, Wash., Nov. 14, 2025 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (NASDAQ:COCP) ("Cocrystal" or the "Company") reports financial results for the three and nine months ended September 30, 2025, and provides updates on its antiviral product pipeline, upcoming milestones and business activities.